Here is your cheat sheet to all therapeutic options that were cleared by the FDA in August 2026 spanning tumor types.
|Videos|June 8, 2011
Dr. Infante on the Future of BRAF Inhibitors in Melanoma
Author(s)Jeffrey R. Infante, MD
Dr. Infante from Sarah Cannon Research Institute on the Future of BRAF Inhibitors in Melanoma
Advertisement
Jeffrey Infante, MD from Sarah Cannon Research Institute on the Future of BRAF Inhibitors in Melanoma
Advertisement
Related to this article
The regulatory path to approval for RP1 plus nivolumab in anti–PD-1–pretreated melanoma ran through 3 BLAs, 2 CRLs, and a divided advisory committee vote.
UroGen submitted an NDA for UGN-103 in recurrent NMIBC, T-DXd improved PFS in first-line HER2-mutant lung cancer, and more.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Camizestrant Plus a CDK4/6 Inhibitor for Emergent ESR1-Mutated HR+, HER2– Advanced Breast Cancer
2
Ivonescimab Meets OS End Point vs Pembrolizumab in First-Line PD-L1+ NSCLC
3
Daraxonrasib Yields Durable Responses in Previously Treated RAS-Mutant NSCLC
4
Novel Therapies Are Poised to Answer Questions and Reinvigorate Hematologic Oncology at SOHO 2026
5